Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/ajh.27180
Keywords
-
Categories
Ask authors/readers for more resources
This study examined the impact of different dosing schedules of venetoclax on overall survival and treatment response rates in newly diagnosed acute myeloid leukemia patients.
Overall survival and response rates of 270 patients with newly diagnosed acute myeloid leukemia receiving venetoclax (Ven) plus hypomethylating agent, stratified by Ven dosing schedule (Cycle 1 Ven 14 vs. 21 vs. 28 days).image
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available